Two Glow & Lovely Skin Creams Withdrawn in UK After OPSS Flags Lilial (BMHCA) and Allergen Labelling Failures

Key Highlights:
Introduction
What the OPSS alert specifies
Why BMHCA (lilial) is a red flag
Fragrance allergens and the harm of inaccurate labelling
How cosmetics regulation and product withdrawal work in the UK
Practical steps for consumers who bought these products
How to read cosmetic labels and spot non-compliant products
Online marketplaces, cross-border sales and the challenge of enforcement
Why products like these can reach shelves
Medical perspective: signs, risks and management of exposure
What retailers and distributors should do when an alert is issued
Broader context: past regulatory actions and the trajectory for fragrance safety
Real-world considerations: how similar incidents have played out
Practical consumer checklist to reduce risk when buying cosmetics
The role of clinicians and reporting systems
What this means for brands and manufacturers
How to stay informed after an alert
Final practical advice and redress expectations
FAQ

Key Highlights:

The Office for Product Safety and Standards (OPSS) has issued safety alerts for Glow & Lovely Hydraglow Rose Enrich Serum Cream 50g and Glow & Lovely Advanced Multi Vitamin Serum in Cream due to the presence of butylphenyl methylpropional (BMHCA, also known as lilial) and incorrect ingredient/allergen labelling.
Both products originate from Pakistan, have distinct barcode references (8961014261721 and 8961014255669), and have been withdrawn from the market by distributor Lajawab Foods Limited; consumers are advised to stop use immediately and contact the distributor for redress.

Introduction

UK authorities have withdrawn two skin creams after identifying serious chemical and labelling breaches. The Office for Product Safety and Standards issued alerts on March 4 after tests found one product contained butylphenyl methylpropional (BMHCA), a fragrance ingredient that is prohibited in cosmetic products because of reproductive toxicity concerns and its potential to cause skin sensitisation. The second product’s ingredients list was inaccurate and did not disclose fragrance allergens, leaving consumers with allergies at risk of adverse reactions. Both items were removed from retail circulation by the distributor, Lajawab Foods Limited. The episode highlights how dangerous or misdescribed cosmetics can enter supply chains and what consumers and retailers should do when alerts are issued.

What the OPSS alert specifies

The OPSS alert identifies two specific Glow & Lovely-branded products packaged in pink-and-white boxes:

Glow & Lovely Advanced Multi Vitamin Serum in Cream — barcode 8961014261721. Hazard: contains butylphenyl methylpropional (BMHCA/lilial), which the regulator says “is not permitted in cosmetic products as it may harm the reproductive system or the health of the unborn child and may cause skin sensitisation.” The product fails to meet the requirements of Regulation (EC) 1223/2009 (the EU Cosmetics Regulation cited by OPSS).
Glow & Lovely Hydraglow Rose Enrich Serum Cream 50g — barcode 8961014255669. Hazard: incorrect ingredient listing and failure to specify fragrance allergens. Consumers with sensitivities to undisclosed allergens may experience adverse effects. This product is likewise deemed non-compliant with Regulation (EC) 1223/2009.

Both items originate from Pakistan. The OPSS instructs anyone who possesses these creams to stop using them immediately and to contact the distributor to request redress. The products have been withdrawn from the market by Lajawab Foods Limited.

Why BMHCA (lilial) is a red flag

Butylphenyl methylpropional—commonly referred to as BMHCA or lilial—is a synthetic fragrance widely used historically for its floral aroma. Safety assessors in Europe identified properties of concern: evidence indicated reproductive toxicity and potential effects on fertility or the unborn child. Regulators also cited skin-sensitising potential, meaning repeated exposure can provoke allergic contact dermatitis in susceptible people.

Regulatory frameworks for cosmetics require ingredients to be assessed and only used when safe at declared concentrations. BMHCA has been evaluated by scientific committees advising regulators, and the chemical is now subject to strict controls or prohibition in many jurisdictions because of its hazard classification. A cosmetic that contains BMHCA and lacks the appropriate safety justification or authorisation will not meet statutory safety requirements, which is the position OPSS has recorded for the Advanced Multi Vitamin Serum in Cream.

From a consumer perspective, presence of BMHCA poses two immediate concerns. First, skin sensitisation can produce chronic contact dermatitis—red, itchy, and sometimes blistering rashes that can persist even after discontinuing the product. Second, the reproductive toxicity assessment elevates the product’s seriousness because it suggests systemic risk for pregnant users or those planning pregnancy, a consideration that makes continued availability on the market unacceptable.

Fragrance allergens and the harm of inaccurate labelling

Fragrances are complex mixtures; regulators require manufacturers to disclose certain fragrance allergens on labels when they exceed concentration thresholds. The aim is straightforward: allow consumers with known sensitivities to identify and avoid products that might provoke allergic reactions.

The Hydraglow Rose Enrich Serum Cream’s ingredients list reportedly contained incorrect information and did not specify fragrance allergens, so consumers with allergies were not able to make an informed choice. Failure to declare allergens can result in immediate contact dermatitis—localized redness, swelling, itching and, in severe cases, blistering—after a single exposure in highly sensitised individuals. Repeated exposures may exacerbate symptoms and complicate diagnosis and management.

Accurate labelling also matters for clinicians. When someone presents with a suspected allergic reaction, the treating clinician relies on the product’s ingredient list to identify the likely allergen and to advise avoidance and possible testing. Mislabelled products undermine clinical diagnosis and place patients at risk of ongoing exposure.

How cosmetics regulation and product withdrawal work in the UK

Cosmetic products placed on the UK market must be safe for human health under normal or reasonably foreseeable conditions of use. Alongside safety, supply chain transparency and accurate labelling are central legal obligations. Key elements in the regulatory framework include:

A designated “responsible person” established for each cosmetic product who must ensure compliance. This role is commonly held by the manufacturer, importer, or distributor placing the product on the market.
A Cosmetic Product Safety Report (CPSR) that assesses risks and justifies the safety of the product for consumers.
Proper labelling in accordance with ingredient naming conventions (INCI — International Nomenclature Cosmetic Ingredient), warnings, batch identifiers and contact details for the responsible person.
Prohibition of substances identified as unsafe or on lists of banned ingredients.

When a regulator such as OPSS receives evidence of non-compliance—either through market surveillance, laboratory testing, adverse reaction reports, or inspections—it can publish a product safety alert and require withdrawal from the market. The distributor or responsible person typically removes the product from sale, notifies sellers, and offers consumers redress, which can mean refund, refund plus return shipping or replacement. Where the breach is severe or criminality is suspected, trading standards or other enforcement bodies may undertake further action, which can include seizure, prosecution or larger-scale market interventions.

The alert concerning the Glow & Lovely products explicitly states the items have been withdrawn by Lajawab Foods Limited, indicating the distributor complied with the OPSS action. OPSS also publishes details to enable consumers and retailers to identify affected items: product names, packaging descriptions and barcodes.

Practical steps for consumers who bought these products

If you own either of the identified Glow & Lovely creams, follow these steps:

Stop using the product immediately. Discontinue application to affected skin areas and avoid further exposure.
Retain the packaging, container and receipt. Keep the outer box and any batch or barcode information. These details are critical when contacting the distributor or reporting the issue.
Contact the distributor, Lajawab Foods Limited, for instructions on redress. The OPSS alert recommends contacting the distributor to request a refund or other remedy. Keep records of your correspondence.
Seek medical advice if you develop symptoms. Mild skin reactions may resolve after stopping the product. For more severe symptoms—spreading rash, significant swelling, blistering, breathing difficulties or signs of systemic reaction—seek urgent medical attention. Inform clinicians about the product and provide a photograph of the label if possible.
Report adverse reactions to the relevant authority. In the UK, adverse reactions and product safety concerns can be reported through official channels (refer to gov.uk product safety alerts and reporting tools) so regulators and public-health officials can track the scale of the problem and identify patterns.
Avoid sharing or gifting an affected product to others. If a container appears used, do not return it to a charity shop or pass it on.

Following these steps protects you and contributes to clearer regulatory oversight.

How to read cosmetic labels and spot non-compliant products

A disciplined approach when buying cosmetics reduces the risk of exposure to unsafe or mislabelled products. Look for the following on the label:

Full INCI ingredient list. Ingredients should be listed using INCI names so that clinicians and safety assessors can identify exact substances.
Batch or lot number and expiry or best-before date where applicable. These identifiers allow returns and help regulators trace particular production runs.
Name and contact details of a responsible person, importer, or distributor on the label or packaging. A lack of contact information is a red flag.
Country of origin and a clear product description. Origin doesn’t inherently mean a product is unsafe, but absence of origin information can be concerning.
Fragrance/allergen disclosure. For the set list of fragrance allergens that require declaration above threshold levels, the label should show those names.
Clean, professional packaging and accurate barcodes. Errors in text, misspellings or poor print quality sometimes indicate low-quality or counterfeit goods.

Avoid products sold with vague or missing ingredient details, and be cautious when images of packaging are the only information presented on an online listing. Keep screenshots of product pages, seller identity and purchase details if you later need to report non-compliance.

Online marketplaces, cross-border sales and the challenge of enforcement

E-commerce has expanded consumers’ access to international brands, but it also complicates regulatory oversight. Cross-border sellers may ship directly to the UK without a UK responsible person designated for regulatory compliance. Marketplaces sometimes host multiple third-party sellers using the same listing, making recalls and enforcement logistically complex.

Retailers and platforms are increasingly required to follow due diligence — removing unsafe listings rapidly when alerted and cooperating with authorities. For consumers, purchasing directly from reputable retailers or the brand’s official channels lowers risk. When buying from international sellers, ensure the listing includes a responsible person for the UK market or that the seller has clear return and contact policies.

Counterfeit or imitation products can be particularly dangerous. They may use cheaper formulations, substitute ingredients, and omit necessary labelling. Instances of counterfeited cosmetics have led to severe skin reactions and even systemic toxicity when hazardous substances were used as cheap substitutes. If a deal looks too good to be true—significantly lower price, no contact details, poor packaging—exercise caution.

Why products like these can reach shelves

Several factors explain how non-compliant cosmetics appear in the market:

Supply-chain lapses. Ingredients or formulations can change during production, and if supplier changes are not reflected in updated safety assessments and labelling, the final product can be non-compliant.
Mislabelled or falsified documentation. A manufacturer or packer may provide incorrect ingredient lists—intentionally or through administrative error—leaving harmful ingredients undisclosed.
Inadequate pre-market checks by importers and distributors, particularly when importers do not take on responsibility as the designated “responsible person.”
Counterfeiting and rebranding. Illicit operators may repackage off-spec or counterfeit products under plausible brand names.
Complexity of enforcing global supply chains. Many brands source ingredients internationally; tracking every batch requires robust systems and regulatory scrutiny that not all operators maintain.

Regulators rely on market surveillance, laboratory testing, adverse reaction reports and cooperation with trading partners to detect issues. When breaches are found, swift removal and public alerts reduce harm and discourage negligent operators.

Medical perspective: signs, risks and management of exposure

Skin reactions to cosmetics range from mild irritation to allergic contact dermatitis. Common signs include redness, itching, dry or scaly patches, swelling and blistering. Reactions typically occur where the product was applied, but severe allergies can spread and occasionally produce systemic symptoms.

Specific to BMHCA (lilial), two medical considerations are paramount:

Skin sensitisation. Sensitisation can develop over repeated exposures. Once sensitised, even tiny amounts of the allergen can trigger reactions.
Potential reproductive toxicity. Although dermal exposure is usually localized, regulators concluded that the systemic effects of BMHCA warranted prohibition. For pregnant people or those trying to conceive, avoidance of products containing banned reproductive toxicants is prudent.

Management steps for suspected cosmetic-related reactions:

Stop using the product immediately and wash exposed areas with mild soap and water.
For localized symptoms, topical emollients and over-the-counter hydrocortisone cream may relieve inflammation; follow clinician guidance.
For severe or spreading reactions, seek GP review. The clinician may recommend topical or oral corticosteroids, antihistamines for symptomatic relief, or referral to dermatology specialists for patch testing if chronic or recurrent reactions occur.
For first-trimester pregnancy concerns or known exposure to a product containing a suspected reproductive toxicant, discuss risks with a healthcare professional. They can provide tailored advice on monitoring and necessary precautions.

Accurate product labelling streamlines diagnosis—when clinicians can see an ingredient list, they can identify candidate allergens and offer appropriate testing and avoidance advice.

What retailers and distributors should do when an alert is issued

Retailers and distributors must act quickly to protect customers and comply with regulation. Recommended operational steps include:

Immediately remove affected stock from shelves and online listings. Secure any remaining inventory to prevent accidental sale.
Communicate clearly with customers who bought the product: issue refunds or replacement options and provide instructions for returning the item if required.
Notify staff and supply-chain partners to halt further distribution.
Preserve product samples, batch records and supplier documentation pending regulatory review or recall investigations.
Cooperate with OPSS, trading standards and other relevant authorities during investigations, providing records and traceability data to enable root-cause analysis.
Review internal compliance processes: ensure the responsible person function is properly assigned and that CPSRs and labelling are up to date.

Transparent, proactive communication preserves consumer trust and limits reputational damage. Failure to act promptly may result in enforcement action and legal consequences.

Broader context: past regulatory actions and the trajectory for fragrance safety

Regulators worldwide have tightened requirements for fragrances and banned ingredients deemed hazardous. Over recent years, scientific reviews have identified certain fragrance ingredients as sensitizers or systemic toxicants. Authorities responded by restricting or prohibiting some substances and by requiring clearer labelling of common allergens.

These moves reflect a broader emphasis on product traceability and consumer information. Authorities now expect operators to maintain clear documentation and to demonstrate the safety of ingredients beyond just the finished product label. Consumers benefit when product safety assessments are rigorous and transparent.

Public safety alerts—like the one issued for the Glow & Lovely products—are a mechanism to communicate findings rapidly to consumers and retailers. They also serve to remind industry members of their obligations and the costs of non-compliance.

Real-world considerations: how similar incidents have played out

Cosmetic recalls and withdrawals are not unusual. They range from labelling errors to contamination and inclusion of banned substances. Outcomes have varied: some incidents resulted in simple local recalls and refunds; others triggered broader regulatory inquiries and tighter enforcement practices.

Lessons from past cases emphasize traceability, rigorous supplier management and the importance of a clear responsible person. In some instances, manufacturers or importers that improved quality controls and transparency restored brand reputation. In other cases where systemic failures occurred, enforcement penalties and long-term market restrictions followed.

For consumers, awareness and prompt reporting matter. When adverse effects are reported, regulators can identify whether a problem is isolated or indicative of a larger trend across batches, brands or distribution channels.

Practical consumer checklist to reduce risk when buying cosmetics

Follow these pragmatic steps when buying cosmetics to minimise exposure to unsafe or mislabelled products:

Buy from established retailers or the brand’s verified channels. Authorized retailers are more likely to stock compliant products and to offer recourse in the event of a recall.
Check that packaging contains full ingredient lists (INCI), batch codes and contact information for the responsible person or distributor.
If purchasing online, retain screenshots of the listing, seller information and payment confirmation. These help trace transactions if a recall is necessary.
Avoid products lacking clear ingredient information or those with inconsistent packaging. Misspelled chemical names and inconsistent branding can signal counterfeit or non-compliant goods.
If you have known allergies, carry a list of ingredients you must avoid and check labels carefully for listed fragrance allergens.
Sign up for official product safety alert feeds (for example, gov.uk product safety alerts) to receive updates about recalls and market withdrawals.

Adopting informed buying habits reduces personal risk and supports the broader market’s compliance incentives.

The role of clinicians and reporting systems

Clinicians treating suspected cosmetic reactions play a dual role: patient care and public-health surveillance. Accurate reporting of suspected adverse reactions supports regulatory authorities in building evidence sets that can justify broader investigations or market actions.

When clinicians suspect an allergic reaction to a product, documenting the product name, batch code and ingredient information in the patient’s records is essential. Referral to dermatology for patch testing may identify the causative allergen, allowing targeted avoidance and counselling.

Regulatory reporting systems capture adverse events and enable trend analysis. Consumers can report symptoms, and clinicians are encouraged to submit formal reports so authorities obtain a complete picture. For regulators, a cluster of reports tied to the same product can trigger laboratory testing or market surveillance.

What this means for brands and manufacturers

Brands and manufacturers must build resilience into product development and supply chains. That includes:

Rigorous supplier audits and raw-material testing to ensure what is claimed on ingredient declarations actually reaches the production line.
Regular review and updating of Cosmetic Product Safety Reports, especially after formulation or supplier changes.
Clear labelling practices adhering to INCI and allergen disclosure rules.
Traceability systems that link finished products to specific raw-material batches and production dates.
Defined roles for the responsible person with documented procedures for recalls and market withdrawals.

Concerted investment in these areas reduces the risk of costly recalls and protects consumers.

How to stay informed after an alert

Stay current with product safety information through official channels. OPSS publishes product safety reports and withdrawal notices on GOV.UK, and local trading standards offices provide guidance on consumer redress in specific cases. Major retailers typically post recall notices and instructions for returns on their websites and social channels. For health concerns, follow NHS guidance and consult your GP or local pharmacist. When in doubt about whether a product in your possession matches the OPSS description, check barcodes and batch numbers against published alerts before disposing or returning the item.

Final practical advice and redress expectations

If OPSS has issued an alert and a distributor has withdrawn the product, consumers should expect straightforward redress: refunds, exchanges or other remedies as specified by the distributor’s stated policy. Keep records—receipts, photographs of packaging, and any correspondence—to substantiate claims. If a distributor is uncooperative, consumer advice services and trading standards can assist in pursuing remedies.

Retailers and online sellers should be prepared to accept returns and comply with regulatory guidance. A transparent, consumer-centered response limits harm and preserves customer trust.

FAQ

Q: Which Glow & Lovely products were withdrawn and how can I identify them?
A: OPSS named Glow & Lovely Advanced Multi Vitamin Serum in Cream (barcode 8961014261721) and Glow & Lovely Hydraglow Rose Enrich Serum Cream 50g (barcode 8961014255669). Both were packaged in pink-and-white cardboard boxes. If you have a product matching those descriptions and barcodes, stop using it and retain the packaging.

Q: What are the specific hazards identified?
A: The Advanced Multi Vitamin Serum in Cream contained butylphenyl methylpropional (BMHCA/lilial), a fragrance ingredient that regulators have classified as a reproductive toxicant and a skin sensitiser. The Hydraglow Rose Enrich Serum Cream had incorrect ingredient listing and failed to declare fragrance allergens, putting sensitive consumers at risk of allergic reactions.

Q: What should I do if I used one of the products and developed a reaction?
A: Stop using the product immediately and wash any affected area with gentle soap and water. For minor symptoms, avoid further exposure and see a pharmacist or GP if symptoms persist. For severe or spreading rash, blistering, breathing difficulties or swelling, seek urgent medical attention. Bring the product and packaging to your appointment and inform the clinician of the OPSS alert.

Q: How do I get a refund or replacement?
A: OPSS advises contacting the distributor, Lajawab Foods Limited, to request redress. Keep proof of purchase, photographs of the product and packaging, and any correspondence. If the distributor fails to resolve the issue, seek guidance from consumer advice services or local trading standards.

Q: Is BMHCA banned in cosmetics?
A: Authorities have identified BMHCA (lilial) as posing reproductive toxicity and skin sensitisation risks, and it is prohibited in cosmetic products under applicable safety standards cited by OPSS. Any cosmetic found to contain BMHCA without lawful justification fails to meet regulatory requirements.

Q: Are other Glow & Lovely products affected?
A: OPSS has listed only the two products specified in its alert. However, if you own other Glow & Lovely products, inspect their labels for full ingredient declarations and responsible person details. If you suspect other items are mislabelled or cause harm, report the matter to OPSS or local trading standards.

Q: How can I report a suspected unsafe cosmetic product?
A: Report suspected adverse reactions or unsafe products via official product safety reporting channels listed on GOV.UK. Include product photos, batch numbers, purchase receipts and a description of symptoms or concerns.

Q: What should retailers and sellers do when OPSS issues an alert?
A: Remove the product from sale immediately, secure remaining stock, notify customers and cooperate with OPSS or trading standards. Provide remedies (refunds or exchanges) to affected customers and preserve records for any investigation.

Q: How can I reduce the chance of buying an unsafe or counterfeit cosmetic?
A: Purchase from reputable retailers or verified brand channels. Check that the label lists INCI ingredients, batch numbers and responsible person contact details. Avoid products with poor print quality or missing information. Keep purchase records and screenshots of online listings.

Q: Where can I find official updates about product safety?
A: OPSS and GOV.UK publish product safety alerts and guidance. Trading standards and consumer advice organizations also provide updates. Check official sources regularly, especially if you purchase cosmetics from smaller importers or cross-border sellers.

If you believe you or someone in your care has been harmed by either of the listed products, preserve the product and packaging, document your symptoms, and report the incident through the official channels to help regulators assess the full scope and prevent further harm.